Aitia

Executive Summary

Aitia is a Cambridge-based biotechnology company that combines Causal AI, multi-omics data, and high-performance computing to build Gemini Digital Twins—in silico models of human disease biology. Founded in 2019, the company aims to accelerate drug discovery and development by uncovering novel disease mechanisms and enabling more efficient clinical development for biopharma partners. Operating at the intersection of AI and life sciences, Aitia's platform has the potential to significantly reduce the time and cost of bringing new therapies to patients. While still in its early stages, the company's innovative approach to leveraging digital twins for disease modeling positions it as a promising player in the AI-driven drug discovery landscape.

Upcoming Catalysts (preview)

• Q3 2026Major Biopharma Partnership70% success
• Q3 2026Series B or C Funding Round75% success
• Q4 2026Validation Publication in Peer-Reviewed Journal60% success